• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Intercure Ltd.

    12/30/25 4:01:09 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INCR alert in real time by email
    6-K 1 form6-k.htm 6-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

     

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the month of December 2025 (Report No. 2)

     

    Commission File Number: 001-40614

     

    INTERCURE LTD.

    (Translation of registrant’s name into English)

     

    85 Medinat ha-Yehudim Street

    Herzliya, 4676670, Israel

    Tel: +972 77 460 5012

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒Form 40-F ☐

     

     

     

     

     

     

    On December 30, 2025, an Annual General Meeting of Shareholders of InterCure Ltd. (the “Company”) approved each of the four proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company’s Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders, dated November 25, 2025, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on November 25, 2025.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      INTERCURE LTD.
       
    Date: December 30, 2025 /s/ Amos Cohen
     

    Amos Cohen

    Chief Financial Officer

     

     

    Get the next $INCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCR

    DatePrice TargetRatingAnalyst
    5/18/2022$13.00Speculative Buy → Buy
    Canaccord Genuity
    More analyst ratings

    $INCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    InterCure upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00

    5/18/22 7:21:05 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    SEC Filings

    View All

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    3/3/26 5:00:07 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    2/19/26 7:35:40 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Intercure Ltd.

    6-K - Intercure Ltd. (0001857030) (Filer)

    12/30/25 4:01:09 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement

    NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced that on February 25, 2026 the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requir

    3/3/26 4:46:00 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million

    InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2025. All amounts ar

    2/19/26 7:00:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million

    InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2025. All amounts are

    2/19/26 7:00:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Financials

    Live finance-specific insights

    View All

    InterCure Reschedules 2022 Full Year Results Conference Call

    NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9

    4/3/23 3:27:01 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

    Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High

    3/31/23 8:00:49 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    InterCure Reports Record Breaking Second Quarter Financial Results

    Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results

    8/15/22 9:15:00 AM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Intercure Ltd.

    SC 13G - Intercure Ltd. (0001857030) (Subject)

    5/16/22 1:02:53 PM ET
    $INCR
    Biotechnology: Pharmaceutical Preparations
    Health Care